Y90 radioembolization in advanced liver cancer of rarely treated tumor entities: prediction of treatment response and survival by clinical and imaging features
- 30 October 2025
- journal article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (1) , 34-40
Abstract
Background: Radioembolization is classically used in patients with hepatocellular carcinoma and secondary hepatic malignancies like colorectal cancer and neuroendocrine tumors. Up to now, data for other hepatic metastasized tumor entities are rare, and it is not clear which clinical and imaging features could predict the outcome. Methods: Data of 60 patients exceptionally treated with radioembolization through the decision of an interdisciplinary board with tumor entities usually not treated by radioembolization were retrospectively analyzed. Hepatic features on cross-sectional preprocedural imaging, for example, like hypervascularization, hepatic tumor burden, maximum diameter, and clinical data, were also analyzed during follow-up. Predictive factors were calculated. Results: Univariate Cox regression showed a significant impact of different features on overall survival, for example, primary malignancy histology in the case of sarcoma, with 25 months median vs. 6 months median overall survival ( P = 0.015). Multivariate Cox regression revealed the two key factors for overall survival: arterial hypervascularization more than rim enhancement (15 vs. 6 months, P = 0.011, hazard ratio: 0.339) and hepatic tumor burden below 10% (18 vs. 5 months, P < 0.001, hazard ratio: 1.04). Conclusion: Preprocedural hypervascularization of liver malignancies and hepatic tumor burden are overall survival predicting factors in tumor entities rarely treated by radioembolization. Consideration of these factors can help to carry out suitable patient selection in the interdisciplinary board for radioembolization.Keywords
This publication has 21 references indexed in Scilit:
- Outcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) RegistryJournal of Vascular and Interventional Radiology, 2024
- Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin MicrosphereCardioVascular and Interventional Radiology, 2024
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective AnalysisCardioVascular and Interventional Radiology, 2022
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice GuidelinesAnnals of Oncology, 2021
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic MetastasesJournal of Vascular and Interventional Radiology, 2020
- Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective StudyJournal of Vascular and Interventional Radiology, 2018
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature ReviewJournal of Vascular and Interventional Radiology, 2009